{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:48:54Z","timestamp":1787579334927,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research and application of clinical characteristic diagnosis and treatment technology in Beijing","award":["grant no. Z221100007422032"],"award-info":[{"award-number":["grant no. Z221100007422032"]}]},{"name":"Beijing Natural Sciences Foundation","award":["Z230021"],"award-info":[{"award-number":["Z230021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00228-024-03717-2","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T04:02:03Z","timestamp":1718942523000},"page":"1409-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of individualized tacrolimus dosing software for Chinese pediatric liver transplantation patients: a population pharmacokinetic approach"],"prefix":"10.1007","volume":"80","author":[{"given":"Siyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"3717_CR1","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","volume":"6","author":"VC McAlister","year":"2006","unstructured":"McAlister VC, Haddad E, Renouf E et al (2006) Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6:1578\u20131585. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01360.x","journal-title":"Am J Transplant"},{"key":"3717_CR2","doi-asserted-by":"publisher","first-page":"CD005161","DOI":"10.1002\/14651858.CD005161.pub2","volume":"2006","author":"E Haddad","year":"2006","unstructured":"Haddad E, McAlister V, Renouf E et al (2006) Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006:CD005161. https:\/\/doi.org\/10.1002\/14651858.CD005161.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3717_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/01.TP.0000056168.79903.20","volume":"75","author":"A Jain","year":"2003","unstructured":"Jain A, Mazariegos G, Pokharna R et al (2003) The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis1. Transplantation 75:1020\u20131025. https:\/\/doi.org\/10.1097\/01.TP.0000056168.79903.20","journal-title":"Transplantation"},{"key":"3717_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T et al (1995) Clinical pharmacokinetics of tacrolimus: Clin Pharmacokinet 29:404\u2013430. https:\/\/doi.org\/10.2165\/00003088-199529060-00003","journal-title":"Clinical pharmacokinetics of tacrolimus: Clin Pharmacokinet"},{"key":"3717_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003088-200140010-00005","volume":"40","author":"MJ Sanchez","year":"2001","unstructured":"Sanchez MJ, Manzanares C, Santos-Buelga D et al (2001) Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 40:63\u201371. https:\/\/doi.org\/10.2165\/00003088-200140010-00005","journal-title":"Clin Pharmacokinet"},{"key":"3717_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14:2119\u20132126. https:\/\/doi.org\/10.2147\/TCRM.S184376","journal-title":"Ther Clin Risk Manag"},{"key":"3717_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","volume":"45","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y et al (2015) Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica 45:840\u2013846. https:\/\/doi.org\/10.3109\/00498254.2015.1021733","journal-title":"Xenobiotica"},{"key":"3717_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/pgs.14.75","volume":"15","author":"V Guy-Viterbo","year":"2014","unstructured":"Guy-Viterbo V, Baudet H, Elens L et al (2014) Influence of donor\u2013recipient CYP3A4\/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics 15:1207\u20131221. https:\/\/doi.org\/10.2217\/pgs.14.75","journal-title":"Pharmacogenomics"},{"key":"3717_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5414\/CP202189","volume":"53","author":"J Yang","year":"2015","unstructured":"Yang J, Liao S, Zhu L et al (2015) Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther 53:75\u201383. https:\/\/doi.org\/10.5414\/CP202189","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3717_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","volume":"36","author":"FT Musuamba","year":"2014","unstructured":"Musuamba FT, Guy-Viterbo V, Reding R et al (2014) Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit 36:54\u201361. https:\/\/doi.org\/10.1097\/FTD.0b013e31829dcbcd","journal-title":"Ther Drug Monit"},{"key":"3717_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","volume":"69","author":"V Guy-Viterbo","year":"2013","unstructured":"Guy-Viterbo V, Scohy A, Verbeeck RK et al (2013) Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69:1533\u20131542. https:\/\/doi.org\/10.1007\/s00228-013-1501-0","journal-title":"Eur J Clin Pharmacol"},{"key":"3717_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bcp.12174","volume":"77","author":"MH Abdel Jalil","year":"2014","unstructured":"Abdel Jalil MH, Hawwa AF, McKiernan PJ et al (2014) Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Brit J Clin Pharmacol 77:130\u2013140. https:\/\/doi.org\/10.1111\/bcp.12174","journal-title":"Brit J Clin Pharmacol"},{"key":"3717_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","volume":"80","author":"M Fukudo","year":"2006","unstructured":"Fukudo M, Yano I, Masuda S et al (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331\u2013345. https:\/\/doi.org\/10.1016\/j.clpt.2006.06.008","journal-title":"Clin Pharmacol Ther"},{"key":"3717_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX et al (2017) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther 42:679\u2013688. https:\/\/doi.org\/10.1111\/jcpt.12599","journal-title":"J Clin Pharm Ther"},{"key":"3717_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s002280100331","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T et al (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57:479\u2013484. https:\/\/doi.org\/10.1007\/s002280100331","journal-title":"Eur J Clin Pharmacol"},{"key":"3717_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","volume":"33","author":"JE Wallin","year":"2011","unstructured":"Wallin JE, Bergstrand M, Wilczek HE et al (2011) Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 33:663\u2013672. https:\/\/doi.org\/10.1097\/FTD.0b013e31823415cc","journal-title":"Ther Drug Monit"},{"key":"3717_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/713650","volume":"2014","author":"L Zhu","year":"2014","unstructured":"Zhu L, Wang H, Sun X et al (2014) The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm (Cairo) 2014:713650. https:\/\/doi.org\/10.1155\/2014\/713650","journal-title":"J Pharm (Cairo)"},{"key":"3717_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bcp.12276","volume":"77","author":"N Kassir","year":"2014","unstructured":"Kassir N, Labb\u00e9 L, Delaloye J-R et al (2014) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients: tacrolimus in paediatric liver transplant recipients. Brit J Clin Pharmacol 77:1051\u20131063. https:\/\/doi.org\/10.1111\/bcp.12276","journal-title":"Brit J Clin Pharmacol"},{"key":"3717_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/tp-20-84","volume":"9","author":"X Chen","year":"2020","unstructured":"Chen X, Wang DD, Xu H, Li ZP (2020) Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Transl Pediatr 9:576\u2013586. https:\/\/doi.org\/10.21037\/tp-20-84","journal-title":"Transl Pediatr"},{"key":"3717_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","volume":"45","author":"WJ Sam","year":"2006","unstructured":"Sam WJ, Tham LS, Holmes MJ et al (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 45:59\u201375. https:\/\/doi.org\/10.2165\/00003088-200645010-00004","journal-title":"Clin Pharmacokinet"},{"key":"3717_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/01.ftd.0000170029.36573.a0","volume":"27","author":"H Zahir","year":"2005","unstructured":"Zahir H, McLachlan AJ, Nelson A et al (2005) Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27:422\u2013430. https:\/\/doi.org\/10.1097\/01.ftd.0000170029.36573.a0","journal-title":"Ther Drug Monit"},{"key":"3717_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/aps.2014.110","volume":"36","author":"Y Lu","year":"2015","unstructured":"Lu Y, Su Q, Wu K et al (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin 36:281\u2013288. https:\/\/doi.org\/10.1038\/aps.2014.110","journal-title":"Acta Pharmacol Sin"},{"key":"3717_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/00007890-200109270-00013","volume":"72","author":"CE Staatz","year":"2001","unstructured":"Staatz CE, Taylor PJ, Lynch SV et al (2001) Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 72:1056\u20131061. https:\/\/doi.org\/10.1097\/00007890-200109270-00013","journal-title":"Transplantation"},{"key":"3717_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhu J-Y et al (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients: tacrolimus population pharmacokinetics and CYP3A5. J Clin Pharm Ther 32:505\u2013515. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00850.x","journal-title":"J Clin Pharm Ther"},{"key":"3717_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","volume":"50","author":"WJ Sam","year":"2000","unstructured":"Sam WJ, Aw M, Quak SH et al (2000) Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Brit J Clin Pharmacol 50:531\u2013541. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00288.x","journal-title":"Brit J Clin Pharmacol"},{"key":"3717_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bcp.15909","volume":"90","author":"K Khamlek","year":"2024","unstructured":"Khamlek K, Komenkul V, Sriboonruang T, Wattanavijitkul T (2024) Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review. Brit J Clin Pharmacol 90:406\u2013426. https:\/\/doi.org\/10.1111\/bcp.15909","journal-title":"Brit J Clin Pharmacol"},{"key":"3717_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1060028019897050","volume":"54","author":"J Shao","year":"2020","unstructured":"Shao J, Wang C, Fu P et al (2020) Impact of donor and recipient CYP3A5*3 genotype on tacrolimus population pharmacokinetics in Chinese adult liver transplant recipients. Ann Pharmacother 54:652\u2013661. https:\/\/doi.org\/10.1177\/1060028019897050","journal-title":"Ann Pharmacother"},{"key":"3717_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJAR Moes","year":"2016","unstructured":"Moes DJAR, Van Der Bent SAS, Swen JJ et al (2016) Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol 72:163\u2013174. https:\/\/doi.org\/10.1007\/s00228-015-1963-3","journal-title":"Eur J Clin Pharmacol"},{"key":"3717_CR29","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.transproceed.2015.09.024","volume":"47","author":"A Argudo","year":"2015","unstructured":"Argudo A, Gonz\u00e1lez De Aledo JM, Al\u00eda P et al (2015) Liver transplant patient carriers of polymorphism cyp3a5*1 donors may need more doses of tacrolimus from the first month after transplantation. Transplant Proc 47:2388\u20132392. https:\/\/doi.org\/10.1016\/j.transproceed.2015.09.024","journal-title":"Transplant Proc"},{"key":"3717_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/archdischild-2013-305212","volume":"99","author":"SN De Wildt","year":"2014","unstructured":"De Wildt SN, Tibboel D, Leeder JS (2014) Drug metabolism for the paediatrician. Arch Dis Child 99:1137\u20131142. https:\/\/doi.org\/10.1136\/archdischild-2013-305212","journal-title":"Arch Dis Child"},{"key":"3717_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","volume":"3","author":"E Fernandez","year":"2011","unstructured":"Fernandez E, Perez R, Hernandez A et al (2011) Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 3:53\u201372. https:\/\/doi.org\/10.3390\/pharmaceutics3010053","journal-title":"Pharmaceutics"},{"key":"3717_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF (2015) Paediatric pharmacokinetics: key considerations. Brit J Clin Pharmacol 79:395\u2013404. https:\/\/doi.org\/10.1111\/bcp.12267","journal-title":"Brit J Clin Pharmacol"},{"key":"3717_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","volume":"61","author":"M Antignac","year":"2005","unstructured":"Antignac M, Hulot JS, Boleslawski E et al (2005) Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 61:409\u2013416. https:\/\/doi.org\/10.1007\/s00228-005-0933-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3717_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","volume":"69","author":"I Oteo","year":"2013","unstructured":"Oteo I, Lukas JC, Leal N et al (2013) Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 69:65\u201374. https:\/\/doi.org\/10.1007\/s00228-012-1300-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3717_CR35","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1002\/jps.24604","volume":"104","author":"X Li","year":"2015","unstructured":"Li X, Wu Y, Sun S et al (2015) Population pharmacokinetics of vancomycin in postoperative neurosurgical patients. J Pharm Sci 104:3960\u20133967. https:\/\/doi.org\/10.1002\/jps.24604","journal-title":"J Pharm Sci"},{"key":"3717_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","volume":"31","author":"A Di Minno","year":"2017","unstructured":"Di Minno A, Frigerio B, Spadarella G et al (2017) Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 31:193\u2013203. https:\/\/doi.org\/10.1016\/j.blre.2017.02.001","journal-title":"Blood Rev"},{"key":"3717_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/1735-5362.301335","volume":"15","author":"D Brocks","year":"2020","unstructured":"Brocks D, Hamdy D (2020) Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring. Res Pharma Sci 15:503\u2013514. https:\/\/doi.org\/10.4103\/1735-5362.301335","journal-title":"Res Pharma Sci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03717-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:05:02Z","timestamp":1722927902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03717-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3717"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03717-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University (ID: 2023-P2-239-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, exemption from informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}